Side-by-side · Research reference

SemaxvsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED12/39 cited

BPhase 3HUMAN-REVIEWED25/54 cited

Semax

Cognitive enhancer · Russian Pharma

200–600 mcg/doseIntranasalKaplan 2017

HumanMechanisticKaplan 2017

~30 minOnset

Intranasal · 2–3×/day during cognitive demand

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

Semax

Survodutide

Primary target

BDNF / NGF expression + monoamine modulationKaplan 2017

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

—

Origin

Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017

—

Antibody development

—

02Dosage Protocols

Parameter

Semax

Survodutide

Standard dose

200–600 mcg / dose intranasalKaplan 2017

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Frequency

2–3× per day during cognitive demand

Once weekly

Lower / starter dose

100 mcg / dose

—

Evidence basis

Human-mechanistic + Russian clinicalKaplan 2017

Phase 2 RCT (obesity) · Phase 3 ongoing

Duration

10–14 day cycles, repeated PRN

—

Reconstitution

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

—

Timing

Morning + early afternoon

—

Half-life

Short plasma; CNS effect lasts ~3–6 hr

—

Route

—

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

Semax

Survodutide

Primary fat target

—

Total body weight, visceral adipose tissue

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

Semax

Survodutide

Nasal irritation

Mild burning or congestion (transient)

—

Sleep disruption

Late-day dosing may interfere with sleep

—

Headache

Uncommon, transient

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

GI symptoms

—

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

Semax

·Pregnancy / breastfeeding

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

Semax

·Active psychiatric instability
·Concurrent strong stimulants

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

Semax

Survodutide

1. Form

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Administration

Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Timing

Morning + early afternoon. Avoid evening (sleep disruption).

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Refrigerate after reconstitution; light-protected.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Caveat

Cycle on/off to avoid neurochemical adaptation.

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

06Stack Synergy

Semax

+ Selank

Moderate

View Selank →

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax: 200–600 mcg intranasal · morning + afternoon
Selank: 150–300 mcg intranasal · midday + early evening
Primary benefit: Cognitive enhancement + stress mitigation

Kaplan 2017 Zaderej 2014

Survodutide

— no documented stacks